Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Clinical trials aiming to develop disease-altering drugs for Alzheimer's disease (AD), a neurodegenerative disorder with devastating consequences, are failing at an alarming rate. Poorly defined inclusion-and outcome criteria, due to a limited amount of objective biomarkers, is one of the major concerns. Non-invasive molecular imaging techniques, positron emission tomography and single photon emission (computed) tomography (PET and SPE(C)T), allow visualization and quantification of a wide variety of (patho)physiological processes and allow early (differential) diagnosis in many disorders. PET and SPECT have the ability to provide biomarkers that permit spatial assessment of pathophysiological molecular changes and therefore objectively evaluate and follow up therapeutic response, especially in the brain. A number of specific PET/SPECT biomarkers used in support of emerging clinical therapies in AD are discussed in this review.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814730 | PMC |
| http://dx.doi.org/10.3389/fphar.2016.00088 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Tc]Tc-Sestamibi/[Tc]NaTcO Subtraction SPECT of Parathyroid Glands Using Analysis of Principal Components.
J Nucl Med Technol
September 2025
Institute of Nuclear Medicine, First Faculty of Medicine, Charles University and the General University Hospital in Prague, Prague, Czech Republic;
The aim of the study was to validate a new method for semiautomatic subtraction of [Tc]Tc-sestamibi and [Tc]NaTcO SPECT 3-dimensional datasets using principal component analysis (PCA) against the results of parathyroid surgery and to compare its performance with an interactive method for visual comparison of images. We also sought to identify factors that affect the accuracy of lesion detection using the two methods. Scintigraphic data from [Tc]Tc-sestamibi and [Tc]NaTcO SPECT were analyzed using semiautomatic subtraction of the 2 registered datasets based on PCA applied to the region of interest including the thyroid and an interactive method for visual comparison of the 2 image datasets.
View Article and Find Full Text PDFAvailability of Radiopharmaceuticals and Imaging Equipment in English-Speaking African Countries.
J Nucl Med Technol
September 2025
Department of Pharmaceutical Sciences, Sefako Makgatho Health Sciences University, Gauteng, South Africa; and.
Radiopharmaceutical services are key in cancer screening, diagnosis, staging, treatment monitoring, detection of remission, and therapy. Unfortunately, due to the high costs of these services, their availability is very limited in developing countries. This study highlights issues related to access to radiopharmaceuticals and imaging equipment in English-speaking African countries.
View Article and Find Full Text PDF[F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson's disease: dosimetry and pharmacokinetics.
Eur J Nucl Med Mol Imaging
September 2025
Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Purpose: Cardiac noradrenergic denervation visualized by meta-[I]iodobenzylguanidine ([I]MIBG) imaging supports the diagnosis of Parkinson's disease (PD). Recently, meta-[F] fluorobenzylguanidine ([F]MFBG) PET demonstrated favorable imaging characteristics compared with [I]MIBG scintigraphy for neuroendocrine tumors. We assessed [F]MFBG dosimetry and myocardial pharmacokinetics in healthy controls and PD patients.
View Article and Find Full Text PDFCardiac nuclear imaging workforce: Trends from Medicare Part B (2013-2022).
J Nucl Cardiol
September 2025
Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, USA. Electronic address:
Background: Cardiac positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are widely used for the assessment of coronary artery disease. While SPECT remains more available, workforce shortages and training demands contribute to geographic disparities in PET availability, impacting patient access to advanced imaging. Therefore, we assessed trends in the U.
View Article and Find Full Text PDFSolid lipid nanoparticles in imaging, diagnostics and theranostics: A review of a decade of innovations and clinical applications.
Colloids Surf B Biointerfaces
September 2025
Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Philadelphia, PA 19104, USA. Electronic address:
The clinical demand for safer, more precise, and functionally versatile imaging tools has intensified with the increasing complexity of disease diagnosis and management. Despite major strides in imaging technologies such as MRI, CT, USG, and PET/SPECT, many modalities are grappled by issues including low specificity, high systemic toxicity of contrast agents, and limited ability to provide real-time functional data. Dreaded by these shortcomings, nanotechnology-based approaches such as liposomes, quantum dots (QDs), polymeric nanoparticles (NPs), gold NPs, lipid NPs, and metallic NPs have emerged as promising alternatives.
View Article and Find Full Text PDF